1. Scrip
  2. >>Business

Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle

Hospital Study Fails

 
• By Andrew McConaghie

The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.

Lungs covid
The inhaled interferon therapy failed to show benefits in hospitalized COVID-19 patients. • Source: Alamy

The chances of Synairgen bringing its inhaled COVID-19 candidate to market have dwindled after a failure in a hospital-based Phase III trial.

The Southampton, UK-based company has been developing its inhaled interferon beta-1a therapy SNG001 for COVID-19 since the beginning of the pandemic in March 2020 but after some encouraging early results in preventing hospitalized

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.